checkAd

     217  0 Kommentare Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 - Seite 2

    The following table provides a summary of Galapagos’ presentations at EBMT 2024:

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Galapagos!
    Short
    29,28€
    Basispreis
    0,26
    Ask
    × 10,63
    Hebel
    Long
    24,72€
    Basispreis
    0,26
    Ask
    × 10,53
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Abstract Title Authors/Presenter Presentation date/time
    Galapagos encore abstracts 
    Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T-Cell Therapy (GLPG5101) in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): Results from the Phase 1 ATALANTA-1 Trial Marie José Kersten, Kirsten Saevels, Sophie Servais, Yves Beguin, Joost S.P. Vermaat, Eva Santermans, Stavros Milatos, Maike Spoon, Marte C. Liefaard, Claire Vennin, Margot J. Pont, Anna D.D. van Muyden, Maria T. Kuipers, Sébastien Anguille Oral presentation number: OS16-04
    Date: 17 April, 12:57-13:06 (session runs 12:30-13:45)
    Session: Oral Session 16: CAR-T outcomes in ALL
    Seven-Day Vein-to-Vein Point-of-Care–Manufactured CD19 CAR T-Cell Therapy (GLPG5201) in Relapsed/Refractory Chronic Lymphocytic Leukemia Including Richter Transformation: Results from the Phase 1 EUPLAGIA-1 Study

     
    Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Julio Delgado, Sergi Betriu, Leticia Alserawan, Ana Triguero, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Anna D.D. van Muyden, Natalia Tovar Oral presentation number: OS16-05
    Date: 17 April, 13:06-13:15 (session runs 12:30-13:45)
    Session: Oral Session 16: CAR-T outcomes in ALL

     

     
    EUPLAGIA-1: Seven-Day Vein-to-Vein Point-of-Care Manufactured GLPG5201 Anti-CD19 CAR-T Cells Display Early Phenotypes in Relapsed/Refractory CLL, including RT Esmée P. Hoefsmit, Sandra Blum, Claire Vennin, Kirsten Van Hoorde, Sergi Betriu,
    Leticia Alserawan, Julio Delgado, Nadia Verbruggen, Anna D.D. van Muyden, Henriëtte Rozema, Ruiz Astigarraga, Margot J. Pont
    Poster number: A073
    Date: 15 April, 18:00-19:00
    Session: Printed poster: CAR-based Cellular Therapy - Clinical

     
    PAPILIO-1: Phase 1/2, Multicenter, Open-Label Study to Evaluate Feasibility, Safety and Efficacy of Point-of-Care–Manufactured Anti-BCMA CAR T-Cell Therapy (GLPG5301) in Relapsed/Refractory Multiple Myeloma Niels W.C.J. van de Donk, Sébastien Anguille, Jo Caers, Marte C. Liefaard, Christian Jacques, Anna D.D. van Muyden Poster number: P049

    Lesen Sie auch

    Seite 2 von 5


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 - Seite 2 Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT) Mechelen, Belgium; 4 April 2024, 22:01 CET – …

    Schreibe Deinen Kommentar

    Disclaimer